December 2005 Sosei Sub-licenses NorLevo to Hexal for Australia December 2005 Sosei Business Update and Revised Financial Forecast Following Acquisition of Arakis (Webcast link) November 2005 Revision Announcement of Financial Forecast for FY2005 November 2005 Arakis Completes Phase I Trials of AD 337 in Fibromyalgia Syndrome October 2005 Arakis and Vectura Announce Start of Phase IIb Trial of NVA237 for COPD October 2005 H.G.F. License Contract September 2005 Arakis Commences Phase IIB Trial for Rheumatoid Arthritis Drug July 2005 Sosei to Acquire Arakis for £106.5 million June 2005 NeuroSolutions' Collaboration with Sosei's Drug Reprofiling Platform® Yields Possible New Treatment for Neuropathic Pain June 2005 Sosei's SOU-001 Project Moves to Phase II Clinical Study May 2005 Sosei Adopts "Company with Committees" System March 2005 Sosei Appoints David Chiswell as Non-Executive Chairman March 2005 Itochu and Sosei Agree on Capital and Business Alliances February 2005 Sosei Files Marketing Authorisation Application for SOT-375 February 2005 Sosei in-license urology drug from Otsuka February 2005 SOT-107 Granted Orphan Designation in Japan February 2005 EPS and Sosei establish a biopharmaceutical JV in China January 2005 Lead antibodies identified under SOA-002 project collaboration 2008 | 2007 | 2006 | 2005 | 2004